Bolder BioTechnology, Inc. Receives U.S. Patent For Process Used To Manufacture Proprietary Second-Generation Protein Pharmaceuticals 
10/19/2005 5:12:36 PM

WHEAT RIDGE, Colo., Feb. 1 /PRNewswire/ -- Bolder BioTechnology, Inc. announced today that it has been granted Patent No. 6,753,165 by the U.S. Patent and Trademark Office. Joe Cox, Company President said, "The patent's claims cover proprietary methods developed by Bolder BioTechnology scientists for manufacturing proteins containing 'free' or unpaired cysteine residues, and proteins and modified proteins produced using these methods. A free cysteine residue can be added to a protein by substitution, addition or insertion, or by eliminating a native cysteine residue that normally forms a disulfide bond with another cysteine residue in the protein. Adding a free cysteine residue to a protein permits targeted modification of the protein with compounds such as polyethylene glycol, which we use to make certain of our long-acting, second-generation protein therapeutics. The ability to target sites for protein modification permits the rational design of homogeneously modified proteins with reproducible, high biological activities, and overcomes the problems of product heterogeneity and low activity typically seen with non-targeted protein modification technologies."

Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create proprietary, long-acting human protein pharmaceuticals for the treatment of hematopoietic and endocrine disorders, cancer and infectious diseases. Research leading to the development of the proprietary methods described in the patent was supported by Small Business Innovation Research grants awarded to Bolder BioTechnology by the National Institutes of Health. For additional information about Bolder BioTechnology, Inc., please visit our web site at

Statements contained herein that are not historical facts are forward- looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company. These factors include, but are not limited to: (1) the Company's ability to successfully complete product research and development, including pre-clinical and clinical studies, and commercialization; (2) the Company's ability to obtain required government approvals; (3) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (4) the Company's ability to develop and commercialize its products before its competitors.

Bolder BioTechnology, Inc.

CONTACT: Joe Cox, Ph.D., President of Bolder BioTechnology, Inc.,+1-303-420-4420, ext. 101